HUTCHMED Ltd (HCM) Form 6-K — Sep 3, 2026
HUTCHMED announced on September 3, 2026 that its subsidiary HUTCHMED Limited entered into an exclusive development and license agreement with a GSK plc subsidiary for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), granting GSK worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize the candidate. Financial terms include a US$110 million upfront payment, up to US$1.185 billion in development, regulatory and commercial milestone payments for a total potential of US$1.295 billion, and tiered royalties on annual net sales, while HUTCHMED retains full development and commercialization rights in Greater China.
Key figures
- Deal Value Usd
- up to US$1.295 billion total (US$110 million upfront plus up to US$1.185 billion in development, regulatory and commercial milestones)
- Royalties
- tiered royalties on annual net sales
- Phase1 Start
- H2 2026
- Upfront Payment Usd
- 110000000
- Initial Indications
- ["colorectal cancer","pancreatic cancer","lung cancer"]
- Clinical Trials Gov Id
- NCT07718581
- Licensed Territories
- worldwide excluding Mainland China, Hong Kong, Macau and Taiwan
- Retained Territories
- Mainland China, Hong Kong, Macau and Taiwan
- Total Potential Consideration Usd
- 1295000000
- Kras Mutation Rate Colorectal Cancer
- approximately 44%
- Kras Mutation Rate Pancreatic Cancer
- up to 89%
- Kras Mutation Rate Lung Adenocarcinoma
- 34%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.